Ernexa Therapeutics Statistics
Total Valuation
ERNA has a market cap or net worth of $10.36 million. The enterprise value is $7.87 million.
Important Dates
The last earnings date was Friday, November 7, 2025, after market close.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ERNA has 7.85 million shares outstanding. The number of shares has increased by 1,252.42% in one year.
| Current Share Class | 7.85M |
| Shares Outstanding | 7.85M |
| Shares Change (YoY) | +1,252.42% |
| Shares Change (QoQ) | +58.83% |
| Owned by Insiders (%) | 52.23% |
| Owned by Institutions (%) | 7.66% |
| Float | 3.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10,360.53 |
| Forward PS | n/a |
| PB Ratio | 2.90 |
| P/TBV Ratio | 6.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7,865.53 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.15.
| Current Ratio | 1.58 |
| Quick Ratio | 1.49 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.85 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -89.29% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -246.33% |
| Revenue Per Employee | $167 |
| Profits Per Employee | -$3.06M |
| Employee Count | 6 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ERNA has paid $28,000 in taxes.
| Income Tax | 28,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.34% in the last 52 weeks. The beta is 6.72, so ERNA's price volatility has been higher than the market average.
| Beta (5Y) | 6.72 |
| 52-Week Price Change | -71.34% |
| 50-Day Moving Average | 1.38 |
| 200-Day Moving Average | 2.27 |
| Relative Strength Index (RSI) | 46.53 |
| Average Volume (20 Days) | 56,801 |
Short Selling Information
The latest short interest is 164,070, so 2.09% of the outstanding shares have been sold short.
| Short Interest | 164,070 |
| Short Previous Month | 713,392 |
| Short % of Shares Out | 2.09% |
| Short % of Float | 4.92% |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, ERNA had revenue of $1,000 and -$18.36 million in losses. Loss per share was -$3.76.
| Revenue | 1,000 |
| Gross Profit | 1,000 |
| Operating Income | -9.92M |
| Pretax Income | -18.31M |
| Net Income | -18.36M |
| EBITDA | -9.85M |
| EBIT | -9.92M |
| Loss Per Share | -$3.76 |
Full Income StatementBalance Sheet
The company has $3.05 million in cash and $552,000 in debt, giving a net cash position of $2.50 million or $0.32 per share.
| Cash & Cash Equivalents | 3.05M |
| Total Debt | 552,000 |
| Net Cash | 2.50M |
| Net Cash Per Share | $0.32 |
| Equity (Book Value) | 3.57M |
| Book Value Per Share | 0.45 |
| Working Capital | 1.24M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$9.41 million and capital expenditures -$22,000, giving a free cash flow of -$9.44 million.
| Operating Cash Flow | -9.41M |
| Capital Expenditures | -22,000 |
| Free Cash Flow | -9.44M |
| FCF Per Share | -$1.20 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -992,200.00% |
| Pretax Margin | -1,831,300.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |